Combinatorial BCL2/BCL2L1 expression predicts clinical response to ruxolitinib in myelofibrosis.

Biomark Res · 2025 · PMC12642052 · PMID 41287119

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Conversely, BCL2L1 showed a trend for up-regulation with mean FC 1.33 (SEM, 0.41).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.